@dansfera: The million-dollar question in biotech finance! 🧐 Is it truly worth the massive investment to repurpose a drug under the 505(b)(2) pathway when exclusivity only lasts three years? Observers are dissecting why that limited IP moat isn't always the golden ticket for boards and investors, even when leveraging existing safety data. It's a deep dive into the cold, hard calculus driving pharmaceutical investment decisions. #DrugRepurposing #BiotechFinance #PharmaFacts #InvestmentStrategy #505b2